• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Overview Of Value Stocks In The Healthcare Sector

    3/28/22 10:44:24 AM ET
    $BDSI
    $BIO
    $BNTX
    $INVA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Get the next $BDSI alert in real time by email

    What are Value Stocks?

    A value stock traditionally has a lower price when compared to stock prices of companies in the same industry. This indicates that the company may be undervalued, as investors are not expressing as much interest in such companies. The most commonly used way to check for value is with the price-to-earnings multiple, or P/E. A low P/E multiple is a good indication that the stock is undervalued.

    The following stocks are considered to be notable value stocks in the healthcare sector:

    1. BioDelivery Sciences Intl (NASDAQ:BDSI) - P/E: 6.82
    2. Innoviva (NASDAQ:INVA) - P/E: 6.83
    3. BioNTech (NASDAQ:BNTX) - P/E: 4.74
    4. Regeneron Pharmaceuticals (NASDAQ:REGN) - P/E: 9.45
    5. Bio-Rad Laboratories (NYSE:BIO) - P/E: 4.01

    BioDelivery Sciences Intl saw an increase in earnings per share from 0.07 in Q3 to $0.62 now. Innoviva's earnings per share for Q4 sits at $0.14, whereas in Q3, they were at 0.9. BioNTech's earnings per share for Q3 sits at $14.56, whereas in Q2, they were at 12.97. Regeneron Pharmaceuticals has reported Q4 earnings per share at $23.72, which has increased by 54.33% compared to Q3, which was 15.37. Bio-Rad Laboratories has reported Q4 earnings per share at $3.21, which has decreased by 13.48% compared to Q3, which was 3.71.

    These 5 value stocks were selected by Benzinga Insights based on quantified analysis. While this methodical judgment process is not meant to make final decisions, our technology can give investors additional perception into the sector.

    Get the next $BDSI alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BDSI
    $BIO
    $BNTX
    $INVA

    CompanyDatePrice TargetRatingAnalyst
    Regeneron Pharmaceuticals Inc.
    $REGN
    3/6/2026$923.00Overweight
    Barclays
    Innoviva Inc.
    $INVA
    2/17/2026$35.00Buy
    BTIG Research
    BioNTech SE
    $BNTX
    2/2/2026$113.00Outperform → Market Perform
    Leerink Partners
    BioNTech SE
    $BNTX
    1/16/2026$142.00Neutral → Buy
    Goldman
    Regeneron Pharmaceuticals Inc.
    $REGN
    1/7/2026$860.00Underperform → Buy
    BofA Securities
    Regeneron Pharmaceuticals Inc.
    $REGN
    12/3/2025$767.00Overweight → Equal-Weight
    Morgan Stanley
    Regeneron Pharmaceuticals Inc.
    $REGN
    11/24/2025$798.00Buy
    Truist
    Regeneron Pharmaceuticals Inc.
    $REGN
    11/24/2025$255.00Buy
    HSBC Securities
    More analyst ratings

    $BDSI
    $BIO
    $BNTX
    $INVA
    SEC Filings

    View All

    SEC Form 20-F filed by BioNTech SE

    20-F - BioNTech SE (0001776985) (Filer)

    3/10/26 6:55:57 AM ET
    $BNTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 6-K filed by BioNTech SE

    6-K - BioNTech SE (0001776985) (Filer)

    3/10/26 6:53:33 AM ET
    $BNTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 6-K filed by BioNTech SE

    6-K - BioNTech SE (0001776985) (Filer)

    3/10/26 6:34:31 AM ET
    $BNTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BDSI
    $BIO
    $BNTX
    $INVA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Regeneron Science Talent Search 2026 Recognizes America's Top Young Scientists, Awarding More Than $1.8 Million to High School Seniors for Innovative Research in Computational Mathematics, Neural Science, and Blood Cancer Treatment

    TARRYTOWN, N.Y. and WASHINGTON, March 10, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Society for Science (the Society) announced that Connor Hill, 17, of State College, Pennsylvania, won the top award of $250,000 in the 2026 Regeneron Science Talent Search (STS), the U.S.'s oldest and most prestigious science and math competition for high school seniors. Key Takeaways: This year marks the 85th anniversary of the Science Talent Search and Regeneron's 10th year as the title sponsor; Regeneron is extending its title sponsorship through 2036, pledging $150 million to fuel the next generation of science and technology leaders.Forty finalists were honored at t

    3/10/26 9:29:56 PM ET
    $REGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BioNTech Announces Fourth Quarter and Full Year 2025 Financial Results and Corporate Update

    BioNTech on track for a catalyst-rich year with six late-stage data readouts expected across immunomodulators, antibody-drug conjugates and mRNA cancer immunotherapies Increased focus on PD-L11/VEGF-A bispecific immunomodulator pumitamig with eight global Phase 3 clinical trials planned to be ongoing for year-end in collaboration with Bristol Myers Squibb Full year 2025 revenues of €2.9 billion2, net loss of €1.1 billion (adjusted3 net loss of €0.1 billion) and diluted loss per share of €4.70 ($5.314) (adjusted3 diluted loss per share of €0.48 ($0.554)) Strong financial position continues to de-risk execution with cash, cash equivalents and security investments of €17.2 billion5Expect 202

    3/10/26 6:45:00 AM ET
    $BNTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    BioNTech and Co-Founders Announce Plan to Pursue Next-Generation mRNA Innovations in Co-Founders-Led New Company as BioNTech Advances Toward Becoming a Multi-Product Company by 2030

    BioNTech continues to sharpen its strategic focus on the growing late-stage clinical pipeline spanning immunomodulator, ADC and mRNA candidatesBioNTech co-founders Ugur Sahin and Özlem Türeci will establish an independent biotechnology company to research and develop next-generation mRNA innovations; management transition by end of 2026Both companies focus on distinct strategic priorities to maximize value for patients and shareholders, with BioNTech planning to contribute related rights and mRNA technologies to the new company in exchange for a minority stakeSigning of binding agreements expected by end of H1/2026 Mainz, Germany, March 10, 2026 (GLOBE NEWSWIRE) – BioNTech SE (NASDAQ:BNTX,

    3/10/26 6:33:07 AM ET
    $BNTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BDSI
    $BIO
    $BNTX
    $INVA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Barclays initiated coverage on Regeneron Pharma with a new price target

    Barclays initiated coverage of Regeneron Pharma with a rating of Overweight and set a new price target of $923.00

    3/6/26 8:35:41 AM ET
    $REGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BTIG Research initiated coverage on Innoviva with a new price target

    BTIG Research initiated coverage of Innoviva with a rating of Buy and set a new price target of $35.00

    2/17/26 7:51:08 AM ET
    $INVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BioNTech downgraded by Leerink Partners with a new price target

    Leerink Partners downgraded BioNTech from Outperform to Market Perform and set a new price target of $113.00

    2/2/26 6:48:45 AM ET
    $BNTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BDSI
    $BIO
    $BNTX
    $INVA
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    May 20, 2022 - FDA Approves First Treatment for Eosinophilic Esophagitis, a Chronic Immune Disorder

    For Immediate Release: May 20, 2022 Today, the U.S. Food and Drug Administration approved Dupixent (dupilumab) to treat eosinophilic esophagitis (EoE) in adults and pediatric patients 12 years and older weighing at least 40 kilograms (which is about 88 pounds). Today’s action marks the first FDA approval of a treatment for EoE. “As researchers and clinicians have gained knowledge about eosinophilic esophagitis

    5/20/22 3:11:09 PM ET
    $REGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BDSI
    $BIO
    $BNTX
    $INVA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Ryan Arthur F sold $78,550 worth of shares (100 units at $785.50), decreasing direct ownership by 0.56% to 17,703 units (SEC Form 4)

    4 - REGENERON PHARMACEUTICALS, INC. (0000872589) (Issuer)

    3/3/26 4:01:53 PM ET
    $REGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Financial Officer Basso Stephen covered exercise/tax liability with 1,244 shares, decreasing direct ownership by 2% to 50,013 units (SEC Form 4)

    4 - Innoviva, Inc. (0001080014) (Issuer)

    2/24/26 4:15:07 PM ET
    $INVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Executive Officer Raifeld Pavel covered exercise/tax liability with 2,986 shares, decreasing direct ownership by 2% to 159,290 units (SEC Form 4)

    4 - Innoviva, Inc. (0001080014) (Issuer)

    2/24/26 4:15:04 PM ET
    $INVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BDSI
    $BIO
    $BNTX
    $INVA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Innoviva Inc.

    SC 13D/A - Innoviva, Inc. (0001080014) (Filed by)

    11/14/24 4:17:40 PM ET
    $INVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by BioNTech SE

    SC 13G/A - BioNTech SE (0001776985) (Subject)

    11/13/24 5:00:57 PM ET
    $BNTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G filed by Innoviva Inc.

    SC 13G - Innoviva, Inc. (0001080014) (Subject)

    5/13/24 1:58:00 PM ET
    $INVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BDSI
    $BIO
    $BNTX
    $INVA
    Leadership Updates

    Live Leadership Updates

    View All

    BioNTech Announces Appointment of Kylie Jimenez to Management Board as Chief People Officer

    Mainz, Germany, January 28, 2026 (GLOBE NEWSWIRE) – BioNTech SE (NASDAQ:BNTX, "BioNTech" or "the Company")) announced today that the Supervisory Board has appointed Kylie Jimenez to the Management Board as Chief People Officer ("CPO") effective March 1, 2026. The appointment is in line with BioNTech's strategy to become a multi-product oncology company by 2030 and underscores the importance of its global, highly skilled workforce in achieving this objective. In the newly created Management Board role, Kylie Jimenez will be responsible for shaping and leading BioNTech's people strategy and its execution in alignment with the Company's priorities and business goals. She will focus on attractin

    1/28/26 8:00:00 AM ET
    $BNTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    The $185B Cancer Surge: Why the FDA's Fast-Track Pivot is Scaling a New Immunotherapy Era

    VANCOUVER, British Columbia, Jan. 14, 2026 (GLOBE NEWSWIRE) -- USANewsGroup.com News Commentary – The global immuno-oncology market is set to explode from its current $35 billion level to a massive $185.69 billion by 2035 as the industry moves toward the coordinated activation of the immune system[1]. This surge is being accelerated by the $69.16 billion genomics revolution, which is now integrating advanced profiling into every oncology workflow to pick winning treatments[2]. This strategic push for registration-ready precision assets fuels the 2026 investment case for Oncolytics Biotech Inc. (NASDAQ:ONCY), ImmunityBio (NASDAQ:IBRX), OS Therapies (NYSE-A: OSTX), BioNTech SE (NASDAQ:BNTX),

    1/14/26 10:39:59 AM ET
    $BNTX
    $CMPX
    $IBRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    BioNTech to Host Innovation Series R&D Day on November 11, 2025

    MAINZ, Germany, October 28, 2025 (GLOBE NEWSWIRE) -- BioNTech SE (NASDAQ:BNTX, "BioNTech" or "the Company")), will host an edition of the Company's Innovation Series R&D Day at 09:00 a.m. Eastern Standard Time (3:00 p.m. CET) on Tuesday, November 11, 2025 in New York City, U.S. On the day, members of BioNTech's leadership team will provide an overview of the Company's strategy and clinical progress across its pipeline. Investors, analysts and the interested public are invited to join the event online via this link. A replay of the webcast will be available shortly after the conclusion of the event and archived on the Company's website for one year following the call. The public may also

    10/28/25 7:45:00 AM ET
    $BNTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BDSI
    $BIO
    $BNTX
    $INVA
    Financials

    Live finance-specific insights

    View All

    BioNTech Announces Fourth Quarter and Full Year 2025 Financial Results and Corporate Update

    BioNTech on track for a catalyst-rich year with six late-stage data readouts expected across immunomodulators, antibody-drug conjugates and mRNA cancer immunotherapies Increased focus on PD-L11/VEGF-A bispecific immunomodulator pumitamig with eight global Phase 3 clinical trials planned to be ongoing for year-end in collaboration with Bristol Myers Squibb Full year 2025 revenues of €2.9 billion2, net loss of €1.1 billion (adjusted3 net loss of €0.1 billion) and diluted loss per share of €4.70 ($5.314) (adjusted3 diluted loss per share of €0.48 ($0.554)) Strong financial position continues to de-risk execution with cash, cash equivalents and security investments of €17.2 billion5Expect 202

    3/10/26 6:45:00 AM ET
    $BNTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    BioNTech to Report Fourth Quarter and Full Year 2025 Financial Results and Corporate Update on March 10, 2026

    MAINZ, Germany, February 24, 2026 (GLOBE NEWSWIRE) -- BioNTech SE (NASDAQ:BNTX, "BioNTech" or "the Company")) will announce its financial results for the fourth quarter and full year 2025 on Tuesday, March 10, 2026. Additionally, the Company will host a conference call and webcast that day at 8:00 a.m. ET (1:00 p.m. CET) for investors, financial analysts and the general public to discuss its financial results and provide a corporate update. To access the live conference call via telephone, please register via this link. Once registered, dial-in numbers and a PIN will be provided. It is recommended to register at least one day in advance. The slide presentation and audio of the webcast will

    2/24/26 6:45:00 AM ET
    $BNTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Bio-Rad Reports Fourth-Quarter and Full-Year 2025 Financial Results

    Bio-Rad Laboratories, Inc. (NYSE:BIO), a global leader in life science research and clinical diagnostics products, today announced financial results for the fourth quarter and full-year ended December 31, 2025. Norman Schwartz, Bio-Rad's Chief Executive Officer, stated: "2025 was a challenging year with geopolitical uncertainty and continued pressure on academic research funding affecting our end markets. While we delivered modest revenue growth and strong free cash flow, our gross and operating margin performance fell below our expectations. The recent acquisition of digital PCR developer Stilla Technologies has been successfully integrated, and we are pleased with the initial market ado

    2/12/26 4:15:00 PM ET
    $BIO
    Biotechnology: Laboratory Analytical Instruments
    Industrials